Solid Tumor CAR-T: China’s 0-to-1 Breakthrough
In June 2026, CARsgen Therapeutics announced that its CLDN18.2-targeting autologous CAR-T product, satricabtagene autoleucel (Saikaize®), received conditional approval from the NMPA for advanced gastric cancer patients who have failed at least second-line therapy, priced at RMB 990,000 per dose (approximately…
